Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You must be kidding right? DDCC is not getting delisted, EVER. You are missing all the fun...DDCC is headed up up up. There has been some very large volume buying recently on several days and this is even before Translock contracts have been announced. This stock is no longer under the radar. You want to see some price movement wait until they announce some Translock deals.
As always, I have dollar signs dancing in my head and 2017 and beyond should be BIG for DDCC.
All those claims that you mention about Translock, I don't have to refute because those claims are outrageous and there is simply no way in the world you can prove them.
P.S. The more you post the more people buy DDCC and the greater the volume. Believe it or not,. it appears that you have become sort of a good luck charm for this stock of late.
With good reason, I see dollar signs dancing in my head from DDCC in 2017 and beyond.
BULLISH on DDCC
I am very bullish on DDCC.
LOL more fiction. Any novels in the works?
Just look at the numbers, DDCC stock price has basically doubled in the past month on very impressive volume. Looks like this stock is not so under the radar anymore. He he who who ha ha. I see dollar signs dancing me in my head.
So be able to back it up. prove it. This is not a fiction board. The real facts are that DDCC stock is up nicely over the past month on very impressive volume.
This stock has a lot of interest even from the doubters that alone should tell you something. The Translock patent is fact which cannot be disputed. I'll take my chances knowing that. I think this stock will move upward soon. I am very bullish on DDCC with a lot of reason to be.
Again with the fiction. You're dreaming pal. On the contrary, the facts show that since the Jan 3 press release the share price of DDCC has gone up up up and the volume has been quite impressive as well.
Posting about the financial condition of DDCC should be based upon actual published articles, documents, or web sites, links, etc. In other words, tangible proof. Otherwise, blank statements unsupported by tangible proof, are not to be believed. Again, this is not the proper forum for fiction and story telling. Lets leave the fiction and story telling to the gifted writers and novelists.
Please just stick to the facts. This is not a place for fiction or story telling. I am extremely bullish on DDCC.
Yeah oh really..ok so prove it, lmao
Stop spreading false rumors that you know they are insolvent. Stick to the facts please.
HAhaha your're back...well guess what we are not even in March 2017. You will soon see even more great things from DDCC this year and the share price should start to reflect that within the next month or two.
Nobody knows if DDCC is not a solvent company. So lets stick to posting what we do know. Keep it to the facts.
Unless you provide us with a link, document article, publication, etc, (tangible proof) to back up your statements, they are pure speculation which have no value. You have no idea whats coming next with DDCC. Stop pretending you do.
Keep laughing but DDCC is a sure winner. The joke will be on you
Absolutely awesome volume lately for DDCC. Interest has been sky high. Smart investors know a great thing when they see it!
you really have a lot to learn about stocks, lol. DDCC is a clear winner. What will you think when you are on the sidelines when DDCC really takes off? If you need a Kleenex I will give you one. Hehehe
I realize that but none of us other than the management of DDCC know the real reason for why that has taken place. So to post disparaging things about a company without the facts is downright deplorable and irresponsible.
Assumptions, hypothesis, misinterpretations of fact, and guesses by outsiders cannot be believable or trustworthy.
I am and will remain extremely bullish on DDCC!!!
Give me a break...no tangible facts have been presented to support these claims. Assumptions, hypothesis, misinterpretations of fact, and guesses by outsiders cannot be believable or trustworthy.
Shorting or Selling DMPI stock right now is VERY UNWISE. Shorts sellers take notice: DMPI stock is NOT A WISE choice to SHORT and here is why:
1) Perfect buyout candidate (I am very confident this company will be bought out) A fundamental of investing is that you never ever short companies with buyout potential.
2) Solid Financials (DMPI fully funded through 2017 as per DMPI May 13th 2016 press release)
3) 3 Orphan Drug Designations (Orphan drug designations are the hottest thing in Biotech right now and makes DMPI a very attractive buyout candidate.
4) Excellent phase II clincial data just received for their brain cancer trials
5) Phase III for brain cancer to be intitated this year
6) uplisting to senior stock exchange next month
7) Warrants may come due this month if DMPI can close above $6.40 for about another 9 days, which would raise about an addition 3 million dollars;
8) A product that treats a variety of different cancers (including Brain cancer (which the most lethal form of cancer), ovarian cancer, cervical cancer, lung cancer, hematological blood cancer; and
9) Approved cancer products in China for lung cancer and leukemia.
So short sellers you would be advised to pick another of the myriad of biotech stocks to shorts and not DMPI because otherwise you could lose your shirt soon. Don't say I didn't warn you
A lot of big catalysts this year for DMPI...
There was not a lot of selling yesterday so don't exagerate. On the contrary, most people are holding onto their shares because they realize how much this stock can go up this year. At this point, I think you would have be crazy to be selling DMPI.
You are so clueless, this stock is not going back down to $1.00 or lower. In addition, there are a BUNCH of big catalysts this year to propel this stock much much much much higher. You know nothing about this company, you are just a lying fradulent day trader who never makes any money.
CO-PILOT SOUNDS LIKE A BITTER SELLER OF DMPI STOCK WHO SOLD WAY WAY WAY WAY TOO SOON..AND CAN'T BUY BACK IN LOWER THAN HE SOLD IT..HE SHOULD KNOW THAT WITH ALL THE GREAT NEWS DMPI HAS BEEN GETTING THAT THE SHARE PRICE OF DMPI SHOULD GO THROUGH THE ROOF THIS YEAR!!!
Why because you say so? You sound like an impatient day trader. DMPI share price should go through the roof this year. The real money to be made with DMPI will go to the patient intelligent investor not to the impatient nickel and dime day traders such as yourself.
Excellent news by DMPI today......
.
In a press release put out by DMPI today, CEO Jeffrey Baccha states in part:
"Our data continues to demonstrate VAL-083's unique cytotoxic anti-cancer mechanism which may provide new treatment opportunities for patients whose cancer has failed or is unlikely to respond to currently available therapies. In particular, the data we have presented in our refractory GBM clinical trial positions us to advance this program into registration-directed Phase III clinical trials and we look forward to discussing our proposed trial design with the FDA," said Jeffrey Bacha, DelMar's chairman & CEO.
"Importantly, new funds raised subsequent to quarter end enable us to fund current operations through 2017 and help position DelMar to qualify to list its common stock on a senior exchange."
EXPECTED NEAR-TERM MILESTONES
•Apply to list our shares on a senior stock exchange;
•Engage the FDA regarding the design of a proposed registration-directed Phase II/III clinical trial for VAL-083 in refractory GBM;
•Initiate the Phase II clinical study at MD Anderson with VAL-083 in patients with GBM at first recurrence/progression;
•Initiate clinical studies in newly-diagnosed GBM patients as an alternative to temozolomide in patients with high expression of MGMT;
•Initiate new clinical trials with VAL-083 in refractory non-small cell lung cancer;
•Initiate registration-directed Phase II/III clinical trials for VAL-083 as a new treatment option for refractory GBM in 2016;
•Continue to pursue pre-clinical research with leading investigators to advance VAL-083 as a potential treatment for other chemo-resistant cancers including ovarian cancer and pediatric medulloblastoma;
•Maximize the value of the VAL-083 pipeline through potential partnering opportunities in high value oncology markets;
•Continue to build the Company's intellectual property portfolio; and
•Continue to implement strategies to enable DelMar to meet qualifications to list its shares on a senior stock exchange